Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03693976
Other study ID # btph-010-2018-SNS01
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 1, 2018
Est. completion date April 15, 2019

Study information

Verified date November 2018
Source Bitop AG
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of this non-interventional study is to investigate the efficacy and tolerability of an Ectoin containing Rhinosinusitis Nasal Spray (SNS01). Within the study, SNS01 will be used either alone as monotherapy or as concomitant therapy in addition to the use of a Xylometazoline-containing decongestant nasal spray. A control group will use a Xylometazoline-containing decongestant nasal spray as monotherapy.

It will be investigated if the dose of the used decongestant nasal spray might be reduced, the development of the disease might be positively influenced and/or the potentially occurring side effects (e.g. dryness of the nasal mucosa, sneezing) might be alleviated by using the Ectoin containing Rhinosinusitis Nasal Spray as concomitant therapy.


Description:

The current non-interventional study aims to investigate the efficacy and tolerability of Ectoin containing Rhinosinusitis Nasal Spray (SNS01) in patients with acute rhinosinusitis. Patients can chose one of three treatment options: a) Ectoin containing Rhinosinusitis Nasal Spray (SNS01), b) decongestant Xylometazoline-containing nasal spray or c) Ectoin containing Rhinosinusitis Nasal Spray (SNS01) and a decongestant Xylometazoline-containing nasal spray.

Efficacy will be studied by documentation of the following symptoms:

- oedema, redness (assessed by rhinoscopy)

- nasal obstruction, nasal secretion, headache/face pain, loss of sense of smell/taste

- sore throat, cough

In parallel, participating patients will document their symptoms and the their quality of life over the entire study duration in patient diaries.

Patients of both genders aged 6 years and above can take part in the study if diagnosed with acute viral rhinosinusitis. The assignment of a patient to a particular treatment is not decided in advance but falls within current practice, and is clearly separated from the decision to include the patient into the study.

Study therapy will be applied in accordance with the respective instructions for use.

Study duration is 7-14 days, depending on the improvement of symptoms. At the end of the study, both the investigators and the patients are asked to judge the efficacy and tolerability of the treatments.


Recruitment information / eligibility

Status Completed
Enrollment 168
Est. completion date April 15, 2019
Est. primary completion date April 15, 2019
Accepts healthy volunteers No
Gender All
Age group 6 Years and older
Eligibility Inclusion Criteria:

- patients with acute viral rhinosinusitis

- presence of common cold symptoms

Exclusion Criteria:

- contraindications in accordance with instructions for use

- acute bacterial rhinosinusitis

- chronic rhinosinusitis

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Xylometazoline Nasal Spray
Application of Xylometazoline Nasal Spray in accordance with the instructions for use
Device:
Ectoin Rhinosinusitis Nasal Spray
Application of Ectoin Nasal Spray (SNS01) in accordance with the instructions for use

Locations

Country Name City State
Germany bitop AG Dortmund

Sponsors (1)

Lead Sponsor Collaborator
Bitop AG

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Physicians' assessment of change of intensity of rhinosinusitis symptoms Both on day 0 and on day 7 (and, if necessary, depending on study duration, on day 14), the physicians will assess rhinosinusitis symptoms oedema, redness of the nose, nasal obstruction, nasal secretion, facial pain/headache, smell/taste dysfunction and the concomitant symptoms dryness of the nasal mucosa and sore throat. Assessment will be carried out based on a 5-point scale (0=none to 4=very strong). Change of symptoms will be assessed comparing symptom scores on day 7 (or day 14, if applicable) to day 0. The investigators will use rhinoscopy, physical examination and interview of the patients for the assessments. day 0 and day 7 and (if necessary, depending on study duration) and on day 14
Secondary Physicians' assessment of general well-being of patients The investigators will assess the well-being of patients using a 4-point scale (good condition to strong illness). day 0 and day 7 and day 14 (if necessary, depending on study duration)
Secondary Patients' assessment of intensity of symptoms and their influence on quality of life Patients will document their rhinosinusitis symptoms and their influence on quality of life (22 parameters in accordance with the "sino-nasal outcome test-22 questionnaire") and the additional symptom "dry nose". They will document their judgement daily in a patient diary using a 6-point scale (0=no problem to 5=as bad as possible). 7 to 14 days (depending on study duration)
Secondary Investigators' and patients' assessment of efficacy of treatments At the end of the study, both investigators and patients will judge the overall efficacy of the treatment based on a 6-point scale (1=very good to 6=unsatisfactory). once on day 7 or day 14 (depending on study duration)
Secondary Assessment of the tolerability of treatments Both investigators and patients will judge the tolerability of the treatments at the end of the study. Both investigators and patients will judge the tolerability based on a 6 point scale (1=very good to 6 = unsatisfactory). once on day 7 or once on day 14 of treatment (depending on study duration)
Secondary Incidence of adverse events/serious adverse events All occurring adverse events/serious adverse events will be documented during the entire study period. 7 to 14 days (depending on study duration)
See also
  Status Clinical Trial Phase
Completed NCT04131686 - NAC Inhalation in the Treatment Of Symptomatic acuTe rhinosinUSitis
Not yet recruiting NCT03517215 - The Development and Testing of a Scaling Strategy for a Community-Based Primary Care Antimicrobial Stewardship Program N/A
Completed NCT05639959 - Efficacy and Safety of New Mometasone Furoate Nasal Spray Formulation in Acute Rhinosinusitis Patients: A Randomized Clinical Trial
Completed NCT00377403 - Treatment of Acute Sinusitis Phase 4
Completed NCT03480100 - Non-interventional Study of Ectoin Nasal Douche (END01) in Patients With Acute Viral Rhinosinusitis
Completed NCT02296814 - Efficacy and Safety of Sinusitis Hevert SL Tablets Compared to Placebo in Adult Patients With Acute, Uncomplicated Rhinosinusitis Phase 4
Completed NCT01553110 - An Observational Study to Evaluate The Relationship of Nasal Mucus Properties and Symptoms
Completed NCT01691677 - beCLomethasone Efficacy in Acute Rhinosinusitis - CLEAR Study Phase 3
Completed NCT01146860 - Efficacy and Safety of a Herbal Medicinal Product (Dry Extract BNO 1016) in Patients With Acute Rhinosinusitis Phase 3
Completed NCT00750750 - Effectiveness and Safety of Once or Twice Daily Mometasone Nasal Spray Versus Amoxicillin Versus Placebo for Treatment of Acute Rhinosinusitis (Study P02683) Phase 2
Completed NCT00751075 - Effectiveness and Safety of Once or Twice Daily Mometasone Nasal Spray Versus Amoxicillin Versus Placebo for Treatment of Acute Rhinosinusitis (Phase 3 Study)(Study P02692) Phase 3